Skip to main content
. 2015 Dec 9;32(12):1248–1262. doi: 10.1007/s12325-015-0270-9

Fig. 1.

Fig. 1

One-way sensitivity analyses for US (above) and Japan (below). G-CSF Granulocyte-colony stimulating factor, PCB Induction bevacizumab plus paclitaxel plus carboplatin followed by single-agent bevacizumab, PemC Induction pemetrexed plus carboplatin followed by single-agent pemetrexed